Phase 1 Dose-Escalation Study of Multiple Dosing Schedules of the Investigational Drug MLN4924, a Nedd8-Activating Enzyme Inhibitor, In Patients with Relapsed and/or Refractory Multiple Myeloma or Lymphoma

被引：0
|
作者：
Shah, Jatin J. [1 ]
Harvey, R. Donald [2 ]
O'Connor, Owen A. [3 ]
Jakubowiak, Andrzej J. [4 ]
Smith, Mitchell R. [5 ]
Orlowski, Robert Z. [1 ]
Mulligan, George J. [6 ]
Smith, Peter G. [7 ]
Pickard, Michael D. [8 ]
Dezube, Bruce J. [9 ]
Lonial, Sagar [2 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Emory Univ, Winship Cancer Inst, Atlanta, GA 30322 USA
[3] NYU Langone Med Ctr, Dept Med, NYU Canc Inst, New York, NY USA
[4] Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA
[5] Fox Chase Canc Ctr, Lymphoma Serv, Philadelphia, PA 19111 USA
[6] Millennium Pharmaceut Inc, Mol Med, Cambridge, MA USA
[7] Millennium Pharmaceut Inc, Discovery, Cambridge, MA USA
[8] Millennium Pharmaceut Inc, Biostat, Cambridge, MA USA
[9] Millennium Pharmaceut Inc, Oncol Clin Res, Cambridge, MA USA
来源：
BLOOD | 2010年 / 116卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1155 / 1155
页数：1
相关论文
共 50 条
  • [31] Investigational Agent MLN9708, An Oral Proteasome Inhibitor, in Patients (Pts) with Relapsed and/or Refractory Multiple Myeloma (MM): Results From the Expansion Cohorts of a Phase 1 Dose-Escalation Study
    Richardson, Paul G.
    Baz, Rachid
    Wang, Luhua
    Jakubowiak, Andrzej J.
    Berg, Deborah
    Liu, Guohui
    Gupta, Neeraj
    Di Bacco, Alessandri
    Hui, Ai-Min
    Lonial, Sagar
    BLOOD, 2011, 118 (21) : 140 - 140
  • [32] Phase I/II dose-escalation study of daratumumab in patients with relapsed or refractory multiple myeloma
    Lokhorst, Henk M.
    Plesner, Torben
    Gimsing, Peter
    Nahi, Hareth
    Minnema, Monique
    Lassen, Ulrik Niels
    Krejcik, Jakub
    Laubach, Jacob
    Lisby, Steen
    Basse, Linda
    Richardson, Paul Gerard Guy
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [33] Amrubicin, a Novel Investigational Anthracycline, in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: Results of a Phase 1 Dose-Escalation Study
    Dinner, Shira N.
    Dunn, Tamara J.
    Medeiros, Bruno C.
    Coutre, Steven E.
    Berube, Caroline
    Gotlib, Jason
    Liedtke, Michaela
    BLOOD, 2012, 120 (21)
  • [34] MLN4924, a Novel Investigational NEDD8 Activating Enzyme Inhibitor, Exhibits Preclinical Activity In Multiple Myeloma and Waldenstrom's Macroglobulinemia through Mechanism Distinct From Existing Proteasome Inhibitors
    McMillin, Douglas W.
    Hunter, Zachary
    Delmore, Jake
    Monrose, Val
    Smith, Peter G.
    Birner, Ann
    Richardson, Paul G.
    Anderson, Kenneth C.
    Treon, Steven P.
    Kung, Andrew L.
    Mitsiades, Constantine S.
    BLOOD, 2010, 116 (21) : 1232 - 1232
  • [35] SYNERGISTIC COMBINATION OF MLN4924, AN INVESTIGATIONAL SMALL MOLECULE INHIBITOR OF NEDD8-ACTIVATING ENZYME (NAE), WITH AZACITIDINE, A HYPOMETHYLATING AGENT, IN PRE-CLINICAL AML CANCER MODELS
    Traore, T.
    Milhollen, M.
    Grossman, S.
    Thomas, M.
    Narayanan, U.
    Garnsey, J.
    HAEMATOLOGICA, 2012, 97 : 435 - 435
  • [36] Pevonedistat (MLN4924), a First-in-Class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukaemia and myelodysplastic syndromes: a phase 1 study (vol 169, pg 534, 2015)
    Swords, R. T.
    BRITISH JOURNAL OF HAEMATOLOGY, 2015, 171 (02) : 294 - 294
  • [37] Evaluation of MLN4924, an investigational NEDD8-activating enzyme (NAE) inhibitor, as a novel targeted agent with single-agent antitumor activity in mantle cell lymphoma (MCL) and Hodgkin lymphoma preclinical models.
    Dawar, Richa
    Barth, Matthew John
    Mavis, Cory
    Skitzki, Jospeh J.
    Czuczman, Myron Stefan
    Klener, Pavel
    Hernandez-Ilizaliturri, Francisco J.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [38] NEDD8-Activating Enzyme Inhibitor MLN4924 Inhibits Both the Tumor Stroma and Angiogenesis in Pancreatic Cancer via Gli1 and REDD1
    Weilin Mao
    Lei Zhang
    Yefei Rong
    Tiantao Kuang
    Dansong Wang
    Xuefeng Xu
    Wenhui Lou
    Jianang Li
    Digestive Diseases and Sciences, 2023, 68 : 1351 - 1363
  • [39] MLN9708, an investigational proteasome inhibitor, in patients (pts) with relapsed/refractory lymphoma: Emerging data from a phase I dose-escalation study.
    Martin, Peter
    Chang, Julie E.
    Rifkin, Robert M.
    Hui, Ai-Min
    Berg, Deborah
    Gupta, Neeraj
    Liu, Guohui
    Di Bacco, Alessandra
    Assouline, Sarit E.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [40] NEDD8-Activating Enzyme Inhibitor MLN4924 Inhibits Both the Tumor Stroma and Angiogenesis in Pancreatic Cancer via Gli1 and REDD1
    Mao, Weilin
    Zhang, Lei
    Rong, Yefei
    Kuang, Tiantao
    Wang, Dansong
    Xu, Xuefeng
    Lou, Wenhui
    Li, Jianang
    DIGESTIVE DISEASES AND SCIENCES, 2023, 68 (04) : 1351 - 1363
12345